RxDoctor Payments Data

Warren Scott, MD

Psychiatry · Pensacola, FLNPI 1023073350

Payments from drug & device makers

$3,118in general payments, 2019–2025

Across 184 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$509
  • AbbVie$410
  • Alkermes, Inc.$271
  • Teva Pharmaceuticals USA, Inc.$253
  • Johnson & Johnson$238
  • Takeda Pharmaceuticals U.S.A., Inc.$222
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,118 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$28,787
Medicare patients
148
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl44$51,817
TrintellixVortioxetine Hydrobromide28$18,320
LybalviOlanzapine/Samidorphan Malate12$18,058
Lurasidone Hcl25$13,194
Aripiprazole105$11,445
SavellaMilnacipran Hcl12$5,453
Clorazepate Dipotassium12$4,127
Quetiapine Fumarate260$3,958
Doxepin Hcl107$2,787
Duloxetine Hcl135$2,620
Trazodone Hcl334$2,591
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$2,387
Bupropion XlBupropion Hcl198$2,111
Clonazepam287$2,079
Lamotrigine162$1,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$238$51,81744 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$222$18,32028 claims
Alkermes, Inc.Lybalvi$271$18,05812 claims
AbbVieSavella$410$5,45312 claims
Almatica Pharma LLCSertraline Hcl$110$80295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →